VEGFA and neoplasm: A second important aspect is whether the ligand binds to only one type of receptor on the tumor cell or a specific receptor in the micro-environment of tumors [e.g., vascular endothelial growth factor receptor (VEGF)] or whether it targets immune cells (e.g., T-cells) or, in the case of multispecific mAbs, both tumor and immune cells.